Azenta Inc (AZTA)

$65.19

+0.08

(+0.12%)

Market is closed - opens 8 PM, 29 Feb 2024

Insights on Azenta Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 172.35M → 154.31M (in $), with an average decrease of 10.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 3.37M → -15.72M (in $), with an average decrease of 565.9% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 68.5% return, outperforming this stock by 20.2%

Performance

  • $64.52
    $66.00
    $65.19
    downward going graph

    1.03%

    Downside

    Day's Volatility :2.24%

    Upside

    1.23%

    downward going graph
  • $36.01
    $69.16
    $65.19
    downward going graph

    44.76%

    Downside

    52 Weeks Volatility :47.93%

    Upside

    5.74%

    downward going graph

Returns

PeriodAzenta IncSector (Health Care)Index (Russel 2000)
3 Months
14.59%
13.2%
0.0%
6 Months
21.02%
9.7%
0.0%
1 Year
48.35%
15.4%
-6.7%
3 Years
-34.93%
30.3%
-19.6%

Highlights

Market Capitalization
3.6B
Book Value
$43.86
Earnings Per Share (EPS)
-0.32
Wall Street Target Price
72.0
Profit Margin
-2.92%
Operating Margin TTM
-16.56%
Return On Assets TTM
-1.47%
Return On Equity TTM
-0.65%
Revenue TTM
641.0M
Revenue Per Share TTM
10.29
Quarterly Revenue Growth YOY
-13.5%
Gross Profit TTM
272.8M
EBITDA
15.4M
Diluted Eps TTM
-0.32
Quarterly Earnings Growth YOY
87.78
EPS Estimate Current Year
0.26
EPS Estimate Next Year
0.46
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
0.04

Analyst Recommendation

Buy
    58%Buy
    41%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Azenta Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 10.45%

Current $65.19
Target $72.00

Company Financials

FY18Y/Y Change
Revenue
631.6M
↓ 8.85%
Net Income
116.6M
↑ 86.19%
Net Profit Margin
18.46%
↑ 9.42%
FY19Y/Y Change
Revenue
781.9M
↑ 23.8%
Net Income
9.9M
↓ 91.52%
Net Profit Margin
1.26%
↓ 17.2%
FY20Y/Y Change
Revenue
897.3M
↑ 14.76%
Net Income
64.9M
↑ 555.74%
Net Profit Margin
7.23%
↑ 5.97%
FY21Y/Y Change
Revenue
513.7M
↓ 42.75%
Net Income
-28.9M
↓ 144.51%
Net Profit Margin
-5.62%
↓ 12.85%
FY22Y/Y Change
Revenue
555.5M
↑ 8.14%
Net Income
-11.3M
↓ 60.91%
Net Profit Margin
-2.03%
↑ 3.59%
FY23Y/Y Change
Revenue
665.1M
↑ 19.73%
Net Income
-14.3M
↑ 26.32%
Net Profit Margin
-2.14%
↓ 0.11%
Q3 FY22Q/Q Change
Revenue
137.6M
↑ 3.64%
Net Income
-5.3M
↓ 24.31%
Net Profit Margin
-3.86%
↑ 1.42%
Q4 FY22Q/Q Change
Revenue
178.4M
↑ 29.66%
Net Income
-11.2M
↑ 111.58%
Net Profit Margin
-6.3%
↓ 2.44%
Q1 FY23Q/Q Change
Revenue
148.4M
↓ 16.8%
Net Income
-2.0M
↓ 82.28%
Net Profit Margin
-1.34%
↑ 4.96%
Q2 FY23Q/Q Change
Revenue
165.9M
↑ 11.82%
Net Income
-1.5M
↓ 26.17%
Net Profit Margin
-0.89%
↑ 0.45%
Q3 FY23Q/Q Change
Revenue
172.4M
↑ 3.86%
Net Income
3.4M
↓ 329.59%
Net Profit Margin
1.96%
↑ 2.85%
Q4 FY23Q/Q Change
Revenue
154.3M
↓ 10.47%
Net Income
-15.7M
↓ 565.9%
Net Profit Margin
-10.19%
↓ 12.15%
FY18Y/Y Change
Total Assets
1.1B
↑ 42.96%
Total Liabilities
378.2M
↑ 137.87%
FY19Y/Y Change
Total Assets
1.5B
↑ 38.42%
Total Liabilities
377.8M
↓ 0.11%
FY20Y/Y Change
Total Assets
1.6B
↑ 2.77%
Total Liabilities
345.5M
↓ 8.54%
FY21Y/Y Change
Total Assets
1.8B
↑ 16.7%
Total Liabilities
494.2M
↑ 43.03%
FY22Y/Y Change
Total Assets
3.7B
↑ 104.24%
Total Liabilities
352.7M
↓ 28.62%
FY23Y/Y Change
Total Assets
2.9B
↓ 22.35%
Total Liabilities
351.2M
↓ 0.43%
Q3 FY22Q/Q Change
Total Assets
3.7B
↓ 0.18%
Total Liabilities
352.7M
↑ 19.6%
Q4 FY22Q/Q Change
Total Assets
3.3B
↓ 11.4%
Total Liabilities
421.0M
↑ 19.36%
Q1 FY23Q/Q Change
Total Assets
3.2B
↓ 1.29%
Total Liabilities
354.6M
↓ 15.78%
Q2 FY23Q/Q Change
Total Assets
3.1B
↓ 5.55%
Total Liabilities
345.9M
↓ 2.45%
Q3 FY23Q/Q Change
Total Assets
2.9B
↓ 5.98%
Total Liabilities
351.2M
↑ 1.53%
Q4 FY23Q/Q Change
Total Assets
2.8B
↓ 2.13%
Total Liabilities
380.7M
↑ 8.38%
FY18Y/Y Change
Operating Cash Flow
74.0M
↓ 23.13%
Investing Cash Flow
-148.5M
-
Financing Cash Flow
170.3M
↓ 756.93%
FY19Y/Y Change
Operating Cash Flow
90.9M
↑ 22.89%
Investing Cash Flow
211.3M
↓ 242.33%
Financing Cash Flow
-191.2M
↓ 212.26%
FY20Y/Y Change
Operating Cash Flow
37.9M
↓ 58.34%
Investing Cash Flow
-22.7M
↓ 110.76%
Financing Cash Flow
-27.0M
↓ 85.86%
FY21Y/Y Change
Operating Cash Flow
149.9M
↑ 295.76%
Investing Cash Flow
-146.3M
↑ 543.52%
Financing Cash Flow
-25.9M
↓ 4.13%
FY22Y/Y Change
Operating Cash Flow
-466.0M
↓ 410.99%
Investing Cash Flow
1.5B
↓ 1101.43%
Financing Cash Flow
-62.8M
↑ 142.27%
FY23Y/Y Change
Operating Cash Flow
17.5M
↓ 103.75%
Investing Cash Flow
431.4M
↓ 70.57%
Financing Cash Flow
-844.1M
↑ 1244.89%
Q3 FY22Q/Q Change
Operating Cash Flow
9.6M
↓ 102.29%
Investing Cash Flow
-374.5M
↓ 1275.13%
Financing Cash Flow
1.8M
↓ 267.88%
Q4 FY22Q/Q Change
Operating Cash Flow
-27.0M
↓ 380.47%
Investing Cash Flow
56.4M
↓ 115.05%
Financing Cash Flow
-504.7M
↓ 28924.67%
Q1 FY23Q/Q Change
Operating Cash Flow
-12.2M
↓ 55.03%
Investing Cash Flow
58.2M
↑ 3.23%
Financing Cash Flow
-416.0K
↓ 99.92%
Q2 FY23Q/Q Change
Operating Cash Flow
16.7M
↓ 237.84%
Investing Cash Flow
214.4M
↑ 268.49%
Financing Cash Flow
-172.1M
↑ 41266.59%
Q3 FY23Q/Q Change
Operating Cash Flow
39.9M
↑ 138.31%
Investing Cash Flow
102.5M
↓ 52.19%
Financing Cash Flow
-166.9M
↓ 3.04%

Technicals Summary

Sell

Neutral

Buy

Azenta Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Azenta Inc
Azenta Inc
-3.56%
21.02%
48.35%
-34.93%
-34.93%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
1.93%
28.19%
68.47%
52.71%
111.72%
Resmed Inc.
Resmed Inc.
-5.35%
11.81%
-15.03%
-7.48%
76.7%
Becton, Dickinson And Company
Becton, Dickinson And Company
1.43%
-14.32%
2.85%
-1.96%
-3.03%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-3.3%
-11.18%
13.01%
26.61%
242.04%
Alcon Ag
Alcon Ag
6.7%
-3.48%
18.96%
15.25%
39.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Azenta Inc
Azenta Inc
1.57
NA
NA
0.26
-0.01
-0.01
NA
43.86
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
76.89
76.89
5.7
6.25
0.15
0.08
NA
37.77
Resmed Inc.
Resmed Inc.
30.3
30.3
1.88
7.45
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
55.57
55.57
1.34
12.94
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
46.1
46.1
9.15
7.61
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
89.16
89.16
1.09
2.74
0.02
0.02
0.0
40.86
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Azenta Inc
Azenta Inc
Buy
$3.6B
-34.93%
1.57
-2.92%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$136.8B
111.72%
76.89
25.24%
Resmed Inc.
Resmed Inc.
Buy
$27.0B
76.7%
30.3
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$69.8B
-3.03%
55.57
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$26.6B
242.04%
46.1
20.12%
Alcon Ag
Alcon Ag
Buy
$39.9B
39.87%
89.16
4.85%

Institutional Holdings

  • Vanguard Group Inc

    10.84%
  • BlackRock Inc

    9.99%
  • Politan Capital Management LP

    8.22%
  • Kayne Anderson Rudnick Investment Management LLC

    8.13%
  • Dimensional Fund Advisors, Inc.

    4.01%
  • NORGES BANK

    3.88%

Corporate Announcements

  • Azenta Inc Dividends June,2021

    In the quarter ending June,2021. Azenta Inc has declared dividend of $0.1

    Read More

Company Information

azenta (nasdaq: azta) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. azenta is headquartered in chelmsford, ma, with operations in north america, europe and asia. for more information, please visit www.azenta.com.

Organization
Azenta Inc
Employees
3500
CEO
Dr. Stephen S. Schwartz
Industry
Technology

FAQs